Shield welcomes US clearance of heart attack test but says Afecta is not all it has to offer
This article was originally published in Clinica
Executive Summary
Shield Diagnostics' heart attack prediction test, Afecta, received US marketing clearance last week. This is a significant milestone, but as managing director David Evans told Maureen Kenny, Shield is keen not to be seen as a one-product company.